Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple breathing test unlock the secrets of chronic cough?

NCT ID NCT03105843

Knowledge-focused Sponsor: Dr. Diane Lougheed Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study investigates how the airways respond to two different challenge tests—mannitol inhalation and a controlled hyperventilation exercise—in people with cough variant asthma, those with chronic cough but normal airway sensitivity, and healthy controls. The goal is to see if these tests trigger similar sensations of breathlessness and airway narrowing in the asthma and cough groups but not in healthy individuals. By comparing these responses, researchers hope to better understand the underlying mechanisms of chronic cough and cough variant asthma.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Methacholine, mannitol, and eucapneic voluntary hyperventilation (EVH) challenge tests
What this could lead to
If successful, this could improve understanding of cough variant asthma and chronic cough, potentially leading to better diagnostic tests or treatments.
What could go wrong
This is a small, early-stage study focused on understanding mechanisms, not on treatment outcomes. Results may not apply to all patients, and the challenges may cause temporary discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

45 people

The number who actually took part.

Started

Mar 2022

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals aged 18-65 years of age with CVA and individuals with methacholine-induced cough but normal airway sensitivity. The following definitions will be used: 1. CVA: chronic cough (≥8 weeks) is the sole or predominant symptom and positive methacholine challenge (PC20 ≤ 16 mg/mL) and history of cough responding to specific asthma treatment (such as inhaled steroid or 1 week trial of bronchodilator); 2. Methacholine-induced cough but normal airway sensitivity: chronic cough (≥8 weeks) is the sole or predominant symptom and negative methacholine challenges (PC20 \> 16 mg/mL). * Individuals aged 18-65 years of age with no history of asthma or chronic cough. Exclusion Criteria: * an exacerbation necessitating a change in medication, emergency department visit or hospitalizations within the previous 4 weeks * inability to perform acceptable spirometry * medical contraindications to methacholine challenge testing * smoking history in excess of 10 pack years Note: Previous treatment with inhaled or systemic corticosteroids is not an exclusion criterion; medication use will be recorded and examined in the analysis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma Cough cough variant asthma Cough-Variant Asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma Cough Cough variant asthma

Contacts and locations

Locations

  • Kingston Health Sciences Centre

    Kingston, Ontario, K7L 2V7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.